Aggrastat is a reversible antagonist of fibrinogen that binds to the glycoprotein IIb/IIIa receptor, thereby blocking the final common pathway to platelet aggregation.
Aggrastat HDB achieves >90% platelet aggregation inhibition
within 10 minutes.1,2
- Platelet inhibition is reversible following cessation of infusion
- The half-life of the HDB regimen is 2 hours and platelet aggregation returns to normal within 4 – 8 hours in approximately 90% of patients
1. Mardikar HM et al. Am Heart J 2007; 154:344e1-344e5
2. Danzi GB et al. AM J Cardiol 2006; 97:489-493